<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059396</url>
  </required_header>
  <id_info>
    <org_study_id>PREDESCI</org_study_id>
    <nct_id>NCT01059396</nct_id>
  </id_info>
  <brief_title>Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal</brief_title>
  <acronym>PREDESCI</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study on the
      effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with
      portal hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appearance of complications of portal hypertension: bleeding (caused by portal hypertension gastropathy and / or esophageal varices), ascites and / or spontaneous bacterial peritonitis(PBE), hepatic encephalopathy. Death from any cause.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the appearance of each of the complications of portal hypertension (ascites, SBP and other bacterial infections, varicose veins or signs of high risk, upper gastrointestinal bleeding portal hypertension, hepatic encephalopathy).</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the development of liver failure.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify the adverse effects of treatment (occurrence and intensity, need to withdraw the treatment).</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess survival.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Portal Hypertension Gastropathy</condition>
  <condition>Esophageal Varices</condition>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>GPVH ≥ 10 mmHg - responders: propranolol.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>GPVH ≥ 10 mmHg nonresponders: carvedilol.</description>
    <arm_group_label>carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo propranolol / carvedilol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 80 years old.

          -  With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and
             analytical image.

          -  No esophageal varices (or with small varices without red signs) in a recent
             videogastroscophy (&lt;3 months before randomization).

          -  Absence of ascites demonstrated by a recent ultrasound (&lt;3 months before the
             randomization).

          -  informed consent

        Exclusion Criteria:

          -  previous decompensation of liver cirrhosis associated with portal hypertension.

          -  GPVH &lt;10 mmHg.

          -  Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the
             splenic or mesenteric vein.

          -  Hepatocellular carcinoma demonstrated by two imaging tests.

          -  Bilirubin&gt; 3 mg / dl (or&gt; 50 micromol / l), platelets &lt;30 x10E9/lo Quick &lt;30%.

          -  Presence of renal insufficiency (serum creatinine&gt; 2 mg / dl or&gt; 200 micromol / l).

          -  Any comorbidity involving a therapeutic limitation and / or a prognosis of life &lt;12
             months.

          -  Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis
             aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma)

          -  Hypersensitivity to β-blockers.

          -  Pregnancy or lactation.

          -  To receive anticoagulant treatment.

          -  Past treatment with nitrated or β-blockers in the two weeks prior inclusion.

          -  Cirrhosis C virus active antiviral therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Càndid Villanueva Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Varea</last_name>
    <phone>+ 34 932275400</phone>
    <phone_ext>3343</phone_ext>
    <email>svarea@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital German Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa M Morillas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosa M Morillas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Bosch, MD</last_name>
      <email>jbosch@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Jaume Bosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Càndid Villanueva, MD</last_name>
      <email>cvillanueva@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Càndid Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Genescà, MD</last_name>
      <email>mirenavarro@ir.vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Joan Genescà, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lérida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carles Aracil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carles Aracil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Puerta del Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Calleja, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose L Calleja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Bañares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Agustín Albillos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 21, 2011</lastchanged_date>
  <firstreceived_date>January 28, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Clinical Trials Unit - Hospital Clínic de Barcelona</name_title>
    <organization>CTU Clínic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
